The aim of this study was to compare the effect of the beta-adrenergic blocker atenolol and the Angiotensin II type 1 (AT1) receptor antagonist losartan on cognitive function in very elderly hypertensive patients. A total of 120 mild to moderate essential hypertensive (DBP 490 and o105 mmHg) patients, aged 75-89 years, were studied. After a 4-week wash-out period on placebo, they were randomized to receive atenolol 50 mg or losartan 50 mg for 24 weeks according to a parallel arm design. At the end of the placebo period and of each active treatment period, BP was measured (by mercury sphygmomanometer, Korotkoff I and V) and cognitive function was evaluated through three different tests (word list memory, word list recall and word list fluency). Both atenolol and losartan were equally effective in reducing SBP (À22.1 and À23.1 mmHg, respectively, Po 0.01 vs baseline) and DBP (À10.3 and À11.2 mmHg, respectively, Po 0.01 vs baseline). Atenolol treatment did not induce significant changes in any test score, whereas losartan significantly increased the score of both the word list memory (+2.2, Po0.05 vs baseline) and the word list recall test (+2.1, Po0.05 vs baseline). The comparison between losartan and atenolol was significant (Po0.05) for both memory tests. These data suggest that in very elderly hypertensive patients, chronic AT1 receptor blockade by losartan could improve cognitive function, in particular immediate and delayed memory.
Introduction
Cognitive impairment and dementia are becoming increasingly prevalent because of demographic changes. [1] [2] [3] In this context, population risk factors for the development of dementia that are potentially modifiable are important to identify. Evidence from longitudinal studies suggested that hypertension in middle or later age is associated with subsequent cognitive impairment, [4] [5] [6] [7] [8] while cross-sectional studies yielded contrasting results. In fact, some authors reported no association between high blood pressure and cognitive impairment, 9, 10 some authors found such a relationship only for subjects aged 70 years and over [11] [12] [13] and other authors observed that higher diastolic (DBP), but not systolic, blood pressure (SBP) values were associated with lower scores in psychometric tests in the elderly. 14, 15 Reasons for discrepancies between longitudinal and cross-sectional studies may include the tendency for BP levels to change with the onset of dementia, 7, 13 the inclusion of individuals with known cerebrovascular disease in cross-sectional studies and the effects of BP lowering therapy on cognitive function. In this regard, little consensus exists in the literature about the influence of antihypertensive drugs on the association between hypertension and cognitive performance, with some studies showing better performance on cognitive function tests in treated as compared to untreated hypertensives, 4, 5, [16] [17] [18] [19] some studies showing poorer performance 20, 21 and other studies showing no difference. [22] [23] [24] [25] Evidence from the literature suggests that antihypertensive drugs may differ in their effect on cognitive function regardless of their hypotensive action. Centrally acting sympathetic nervous system blocking agents, such as methyldopa and lipophilic beta-blockers like propranolol, have been reported to interfere negatively with memory and cognitive function, [26] [27] although other studies have shown no significant adverse effect of beta-blockers including propranolol on cognitive performances.
reported with diuretics 16, 28, 30 and calcium antagonists. 17, 29, [32] [33] [34] Only antihypertensive drugs that interfere with the renin-angiotensin system seem to be effective in preventing cognitive decline and even improving cognitive function in hypertensive patients. Thus, in both experimental and clinical studies ACE inhibitors and the more recent Angiotensin II (AngII) antagonists have been shown to influence mental function positively, improving learning and memory. [35] [36] [37] [38] [39] With this background, the aim of the present study was to compare the effect of the betaadrenergic blocker atenolol and the Angiotensin II type 1 receptor (AT1) blocker losartan on memory function in very elderly hypertensive patients, who are likely to be most vulnerable to the effects of antihypertensive drugs on cognitive function. 40, 41 
Materials and methods
We enrolled 120 outpatients, 54 males and 66 females, aged 75-89 years (mean age: 81.3 years) with mild to moderate essential hypertension (DBP490 and o105 mmHg and SBP o200 mmHg). Patients with contraindications to beta-blockers, previous stroke or transient ischaemic attack, myocardial infraction within the last 6 months, congestive heart failure, peripheral vascular disease, renal failure and chronic severe liver disease were excluded from the study as were those taking psychotropic medications that could interfere with cognitive function.
The study protocol was approved by the local ethical committee and informed consent was obtained from each patient prior to the start of the study.
After a 4-week wash-out period, during which any previous antihypertensive therapy was gradually discontinued and placebo was administered, the patients were randomised to receive atenolol or losartan according to a double-blind parallel design. The randomised active treatment period lasted for 24 weeks and started with atenolol 50 mg or losartan 50 mg. After 6 weeks, patients whose BP was not adequately controlled (DBP 490 mmHg) were titrated to the higher doses of study medications (atenolol 100 mg or losartan 100 mg). After 12 weeks, patients whose DBP continued to be 490 mmHg were discontinued (three in the atenolol and two in the losartan group; these patients were not included in the final analysis). Patients were checked at the end of the placebo period and after 6, 12 and 24 weeks of treatment. At each visit compliance to treatment was measured by tablet count and adverse events were all registered. At the end of the placebo period and the active treatment period, BP was measured and cognitive functions were evaluated. Blood pressure measurements were performed at approximately the same time of the day (in the morning prior to the drug dose) using a standard sphygmomanometer (Korotkoff I and V) after the patient had been resting in the sitting position for 10 min. The average of three consecutive measurements (with at least a 1-min interval between them) was recorded.
Three tests of cognitive function were administered: the word list memory test, the word recall test and the word list fluency Test. The first two tests measure immediate memory and delayed memory: 42 the memory test requires the immediate recall of 10 standardised words, and the recall test involves the recollection of the 10 words learned previously after a delay of 20 min. Scores for both tests range from 0 to 10, with higher scores indicating better performance. The word list fluency test measures verbal production, semantic memory and language; 43 in this test, subjects name as many animals as possible in 60 s. Higher scores indicate better performance.
Descriptive statistics were performed for all variables measured. 'Per protocol' efficacy analysis was performed on patients who complied fully with all protocol criteria. The 95% confidence intervals (95% CI) for within-group changes from baseline were calculated. Differences between group were compared by ANOVA with Bonferroni correction; Po0.05 was considered statistically significant. The data are expressed as mean 7 s.d.
Results
In total, 109 patients completed the study. Out of the 120 enrolled patients, five (three to atenolol and two to losartan) withdrew without having registered efficacy data, and four (three to atenolol and one to losartan) withdrew due to adverse events. Thus 111 patients, 54 to atenolol and 57 to losartan, were considered valid for the final evaluation. There were no significant differences in patient characteristics at baseline (Table 1) .
Both atenolol and losartan significantly lowered SBP and DBP values as compared to baseline without differences between the two treatments ( Table 2 ). The mean decrease in DBP was 10.3 mmHg with atenolol and 11.2 mmHg with losartan, that is, Losartan and memory in elderly hypertensives R Fogari et al a mean difference of 0.9 mmHg in favour of losartan. The 95% CI was À1.1 to 2.8. The difference measured is less than 2.5 mmHg (the clinically relevant difference) and is within the equivalence difference. This permits the conclusion that the two treatments are equivalent. The mean decrease in SBP was 22.1 mmHg with atenolol and 23.1 mmHg with losartan, that is, a mean difference of 1.0 mmHg in favour of losartan with 95% CI À2.9 to 4.6 mmHg.
As expected, HR was significantly lower in the atenolol group (À13.2 bpm) than in the losartan group (À0.6 bpm) (Po0.01).
The losartan group had a significant improvement in both memory tests: the word list memory score increased by 2.2 (Po0.05 95% CI -2.8 to -0.21) and the word list recall score increased by 2.1 (Po0.05 95% CI -2.6 to -0.1). In the atenolol group, the mean changes were not statistically significant in both memory tests. The comparison between losartan and atenolol was significant (Po0.05) for both memory tests. The score of the word fluency test was not significantly modified by both treatments.
Safety and adverse events analysis
All patients were evaluated for safety considering adverse events, intercurrent diseases, drop-outs and death and treatment group. A total of 120 patients (60 atenolol to 60 losartan) were included in the safety analysis. A total of 39 episodes of adverse events (31 with atenolol, eight with Losartan ) were reported in 21 patients (16 to atenolol, five to losartan). Innall, 10 patients on atenolol had adverse events during the low-dose treatment phase and six during the high-dose treatment; for losartan, three patients had adverse events during low-dose and 2 during high-dose therapy. In the atenolol group, the most frequent type of adverse events were fatigue (15 episodes), cold extremities (13 episodes) and dizziness (four episodes). In the losartan group, headache (three episodes) and nausea (three episodes) were more frequent. No death occurred during the study. In the atenolol group, six patients dropped out of which three drop-outs were due to adverse events (5% of the patients on atenolol), while in the losartan group there was one (1.6%). One serious adverse event (bradycardia with A-V II degree block) occurred in the atenolol group: it was resolved with treatment withdrawal.
Discussion
These results show that both atenolol and losartan have the same antihypertensive efficacy in very elderly hypertensive patients, however, only losartan improves memory function, both the immediate and the delayed one.
This suggests that losartan can have a positive effect not only on BP but also on impaired cognitive function. Such an improvement is different to explain.
Increasing evidences indicate that brain angiotensin II (AII) and some of its fragments, that is AII [3] [4] [5] [6] [7] [8] (AIV) and AII, [3] [4] [5] [6] [7] either ageing directly or by modulation of the activity of other transmitters, are involved in cognitive processes, including learning and memory. 44, 45 Although the role of the brain angiotensins in humans remains to be fully explored, experimental studies have demonstrated that intracerebroventricular administration of AII and its fragments facilitated acquisition in active conditioning trials and retention in a passive avoidance situation. [46] [47] [48] The facilitatory effects of angiotensins on memory has been connected mainly with the recently discovered AT4 receptors, which preferentially bind AIV and AII [3] [4] [5] [6] [7] and are found in brain areas distinct from those possessing AT1 and AT2 receptors (mainly in the neocortex, hippocampus, dentate gyrus, thalamus and cerebellum). [49] [50] [51] However, considerable evidence suggests significant, although different, involvement of AT1 and AT2 receptors in cognitive processes. 52, 53 In various animal models of learning and memory, inhibitors of the renin-angiotensin system, particularly ACE inhibitors and AII antagonists, have been reported to have potential nootropic effects. [54] [55] [56] [57] In particular, losartan has been demonstrated to enhance retention performance in spatial and shortterm working memory [55] [56] [57] and to reverse the Losartan and memory in elderly hypertensives R Fogari et al scopolamine-induced memory deficit in delayed matching and inhibitory avoidance models. 56, 58 Although few data are available in humans, clinical data with AII antagonists tend to support experimental findings. Thus, losartan has been shown to improve cognitive functions in hypertensive patients. 38, 39 In agreement with these observations, the results of the present study indicated that in very elderly hypertensive patients, losartan treatment improved cognitive performance. This was particularly true in scales evaluating immediate and delayed memory, although an increasing trend was also observed in the score of the word list fluency test, which measured semantic memory and language.
The memory-enhancing action of losartan might be due to the ability of the drug to cross the brain barrier and to unmask the AT2 receptors as a consequence of AT1-receptor blockade. 59 The augmenting action of endogenous AII, released in response to the AT1-receptor blockade, via AT2 receptors, might result in memory-enhancing effects, possibly by modulation of dopaminergic and noradrenergic transmission. Blockade of AII at the AT1 receptor level by losartan might also result in an increased synthesis of angiotensin IV; this peptide selectively binds to AT4 receptors, whose activation has been demonstrated to participate in memory acquisition and recall, perhaps via modulating neurotransmitters release and/or remodelling cholinergic and glutaminergic pathways in the hippocampus. [49] [50] [51] Unlike losartan, atenolol treatment did not significantly affect cognitive performance, which is in agreement with some previous observations showing no improvement, but also no deterioration in cognitive function of hypertensive patients treated with beta-blockers. [28] [29] [30] [31] [32] The difference between losartan and atenolol in their effects on cognitive function did not depend on their antihypertensive effect, since the BP reduction was similar with the two drugs.
In conclusion, the results of this study suggest that in very elderly hypertensive patients losartan can have a positive effect not only on BP control but also on cognitive function and, in safety terms, offers some advantage over atenolol. It remains to be determined whether the benefits of treating hypertension with a drug that seems to reduce the rate of cognitive decline would extend to primary prevention of dementia.
